1. Home
  2. PSNL vs NTLA Comparison

PSNL vs NTLA Comparison

Compare PSNL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Personalis Inc.

PSNL

Personalis Inc.

SELL

Current Price

$15.65

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

SELL

Current Price

$11.41

Market Cap

1.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PSNL
NTLA
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
PSNL
NTLA
Price
$15.65
$11.41
Analyst Decision
Hold
Buy
Analyst Count
5
20
Target Price
$15.17
★ $23.11
AVG Volume (30 Days)
2.1M
★ 5.3M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.58
27.43
EPS
★ N/A
N/A
Revenue
★ $69,648,000.00
$67,671,000.00
Revenue This Year
$21.10
N/A
Revenue Next Year
$30.66
$143.36
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$4.96
$7.95
52 Week High
$18.89
$28.24

Technical Indicators

Market Signals
Indicator
PSNL
NTLA
Relative Strength Index (RSI) 40.41 41.88
Support Level $13.68 $10.15
Resistance Level $16.58 $13.50
Average True Range (ATR) 0.35 0.76
MACD -0.09 -0.10
Stochastic Oscillator 10.70 19.70

Price Performance

Historical Comparison
PSNL
NTLA

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: